Package Leaflet: Information for the User
Capenon 20 mg/5 mg film-coated tablets
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Capenon contains two active substances called olmesartan medoxomil and amlodipine (as amlodipine besylate). Both substances help to control high blood pressure.
The action of both substances contributes to preventing the narrowing of blood vessels, so that they relax and blood pressure decreases.
Capenon is used to treat high blood pressure in patients whose blood pressure is not adequately controlled with olmesartan medoxomil or amlodipine alone.
Do not take Capenon:
If you think you may be allergic, inform your doctor before taking Capenon.
Warnings and precautions
Consult your doctor or pharmacist before starting to use Capenon.
Tell your doctorif you are taking any of the following medicines used to treat high blood pressure (hypertension):
Your doctor may need to check your kidney function, blood pressure, and blood electrolyte levels (e.g. potassium) at regular intervals.
See also the information under the heading “Do not take Capenon”.
Tell your doctorif you have any of the following health problems:
Contact your doctor if you suffer from severe, persistent diarrhea that causes significant weight loss. Your doctor will assess your symptoms and decide how to proceed with your blood pressure treatment.
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Capenon. Your doctor will decide whether to continue treatment. Do not stop taking Capenon on your own.
As with any other medicine that lowers blood pressure, excessive lowering of blood pressure in patients with impaired blood flow to the heart or brain may cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
You must inform your doctor if you are pregnant or think you might be. It is not recommended to use Capenon at the start of pregnancy, and it must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken at this stage (see section “Pregnancy and breast-feeding”).
Children and adolescents (under 18 years)
Capenon is not recommended for children and adolescents under 18 years.
Using Capenon with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Capenon” and “Warnings and precautions”).
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Taking Capenon with food and drink:
Capenon can be taken with or without food. Take the tablets with a little liquid (e.g. a glass of water). If possible, take your daily dose at the same time each day, e.g. at breakfast time.
People taking Capenon must not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice can lead to an increase in the levels of the active ingredient amlodipine in the blood, which can cause an unpredictable increase in the blood pressure-lowering effect of Capenon.
Elderly patients
If you are over 65 years old, your doctor will regularly check your blood pressure whenever your dose is increased, to make sure it does not decrease too much.
Black patients
As with other similar medicines, the blood pressure-lowering effect of Capenon is somewhat smaller in black patients.
Pregnancy and breast-feeding
Pregnancy
You must inform your doctor if you are pregnant or think you might be.
Your doctor will advise you to stop taking Capenon before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Capenon. It is not recommended to use Capenon at the start of pregnancy, and it must not be taken when you are more than 3 months pregnant, as it may cause serious harm to your baby if taken at this stage.
If you become pregnant while taking Capenon, inform and consult your doctor immediately.
Breast-feeding
Inform your doctor if you are breast-feeding or about to start breast-feeding. It has been shown that amlodipine passes into breast milk in small amounts. Capenon is not recommended for breast-feeding mothers, and your doctor may choose another treatment if you wish to breast-feed, especially if your baby is newborn or premature.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
During treatment for high blood pressure, you may feel drowsy, feel sick, or have headaches. If this happens, do not drive or use machines until the symptoms have gone away. Consult your doctor.
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, i.e. it is essentially “sodium-free”.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
If you take more Capenon than you should
If you take more tablets than you should, you will probably experience a drop in blood pressure, accompanied by symptoms such as dizziness, and a fast or slow heart rate.
If you take more tablets than you should, or a child accidentally swallows some tablets, contact your doctor or the nearest emergency department immediately and take the medicine pack or this leaflet with you.
Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing that may develop up to 24-48 hours after ingestion.
In case of overdose or accidental ingestion, consult the Toxicology Information Service. Telephone 91 562 04 20.
If you forget to take Capenon:
If you forget to take a dose, take your normal dose the next day. Do nottake a double dose to make up for forgotten doses.
If you stop taking Capenon:
It is important to continue taking Capenon unless your doctor tells you to stop.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. If they occur, they are often mild and do not require discontinuation of treatment.
The following adverse effects may be serious, although they affect only a small group of people:
During treatment with Capenon, allergic reactions can occur, which can affect the whole body, with inflammation of the face, mouth, and/or larynx (vocal cords), along with itching and skin rash. If this happens to you, stop taking Capenon and consult your doctor immediately.
Capenon may cause a marked decrease in blood pressure, in susceptible patients, or as a result of an allergic reaction. This can cause fainting or severe dizziness. If this happens to you, stop taking Capenon, consult your doctor immediately, and remain lying down in a horizontal position.
Unknown frequency: If you experience yellowing of the whites of the eyes, dark urine, skin itching, even if you started treatment with Capenon a long time ago, contact your doctor immediatelywho will evaluate your symptoms and decide how to continue treatment for blood pressure.
Other possible adverse effects with Capenon:
Frequent (may affect up to 1 in 10 people):
Dizziness; headache; swelling of the ankles, feet, legs, hands, or arms; fatigue.
Uncommon (may affect up to 1 in 100 people):
Dizziness when standing up; lack of energy; tingling or numbness of the hands or feet; vertigo; noticing heartbeats; rapid heartbeat; low blood pressure with symptoms such as dizziness, dizziness; difficulty breathing; cough; nausea; vomiting; indigestion; diarrhea; constipation; dry mouth; pain in the upper abdomen; skin rash; cramps; pain in arms and legs; back pain; urge to urinate; sexual inactivity; inability to have or maintain an erection; weakness.
Some changes in the results of certain blood tests have also been observed:
Increase, as well as decrease, of potassium levels in the blood, increase of creatinine levels in the blood, increase of uric acid levels, increase in the values of liver function tests (gamma glutamyl transferase levels).
Rare (may affect up to 1 in 1,000 people):
Hypersensitivity to the medicine; fainting; redness and feeling of heat in the face; red hives with itching (urticaria); facial inflammation.
Adverse effects reported with the use of olmesartan medoxomil or amlodipine alone, but not with Capenon, or with a higher frequency:
Olmesartan medoxomil
Frequent (may affect up to 1 in 10 people):
Bronchitis; sore throat; nasal congestion and secretion; cough; abdominal pain; viral gastroenteritis; diarrhea; indigestion; nausea; joint and bone pain; back pain; blood in the urine; urinary tract infection; chest pain; flu-like symptoms; pain. Changes in the results of blood tests, such as increased levels of a type of fat (hypertriglyceridemia); increased uric acid and urea in the blood and increased values of liver and muscle function tests.
Uncommon (may affect up to 1 in 100 people):
Reduction in the number of a type of blood cells called platelets, which can easily cause bruising or prolong bleeding time; rapid allergic reactions, which can affect the whole body and cause respiratory problems, as well as a rapid drop in blood pressure, which can even cause fainting (anaphylactic reactions); angina (pain or discomfort in the chest, known as angina pectoris); itching; skin rash; allergic skin rash; urticaria; facial swelling; muscle pain; discomfort.
Rare (may affect up to 1 in 1,000 people):
Inflammation of the face, mouth, and/or larynx (vocal cords); acute kidney failure and kidney failure; lethargy; intestinal angioedema: swelling in the intestine that occurs with symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Amlodipine
Very frequent (may affect more than 1 in 10 people):
Edema (fluid retention).
Frequent (may affect up to 1 in 10 people):
Abdominal pain; nausea; swelling of the ankles; feeling of sleep; redness and feeling of heat in the face, visual disturbances (including double vision and blurred vision), noticing heartbeats, diarrhea, constipation, indigestion, cramps, weakness, difficulty breathing.
Uncommon (may affect up to 1 in 100 people):
Difficulty sleeping; sleep disorders; mood changes including anxiety; depression; irritability; tremors; taste disturbances; fainting; ringing in the ears (tinnitus); worsening of angina pectoris (pain or discomfort in the chest); irregular heartbeat; nasal secretion or congestion; hair loss; purple spots or spots on the skin due to small hemorrhages (purpura); skin discoloration; excessive sweating; skin rash; itching; red hives with itching (urticaria); joint or muscle pain; urination problems; need to urinate at night; increased need to urinate, increased breast size in men, chest pain; pain; feeling of discomfort; weight gain or loss.
Rare (may affect up to 1 in 1,000 people):
Confusion.
Very rare (may affect up to 1 in 10,000 people):
Reduction in the number of white blood cells, which could increase the risk of infections; reduction in the number of a type of blood cells called platelets, which could lead to bruising and prolonged bleeding time; increased glucose in the blood; increased muscle tension or greater resistance to passive movement (hypertonia); tingling or numbness of the hands or feet; heart attack; inflammation of blood vessels; inflammation of the liver or pancreas; inflammation of the stomach wall; gum thickening; elevated liver enzymes; yellowing of the skin and eyes; increased sensitivity of the skin to light; allergic reactions: itching, rash, inflammation of the face, mouth, and/or larynx (vocal cords), along with itching and rash, severe skin reactions, including intense skin rash, urticaria, redness of the body skin, severe itching, blisters, peeling, and skin inflammation, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) sometimes very severe.
Unknown frequency (cannot be estimated from the available data):
Tremors, rigid posture, mask-like face, slow movements, and unsteady gait.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after "CAD.:". The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be thrown down the drain or into the trash. Deposit the packaging and medicines that you no longer need in the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This way, you will help protect the environment.
Composition of Capenon:
The active ingredients are olmesartan medoxomil and amlodipine (as besylate).
Each tablet contains 20 mg of olmesartan medoxomil and 5 mg of amlodipine (as besylate).
The other components are:
Core of the tablet: Pregelatinized cornstarch, silified microcrystalline cellulose, sodium croscarmellose, and magnesium stearate.
Coating of the tablet: Poly (vinyl alcohol), macrogol 3350, talc, and titanium dioxide (E-171).
Appearance of the product and package contents
Capenon 20 mg/5 mg film-coated tablets are white, round tablets with the inscription C73 on one side.
Capenon film-coated tablets are available in packages of 28, 56, 98, and 10 x 28 film-coated tablets, and in packages with precut unit-dose blisters of 50 and 500 film-coated tablets.
Not all packages are marketed.
Marketing authorization holder
Daiichi Sankyo España, S.A.
Paseo del Club Deportivo nº1,
Edificio 14, Planta baja izquierda
28223 Pozuelo de Alarcón - Madrid
Manufacturer
Daiichi Sankyo Europe GmbH
Luitpoldstrasse 1
85276 Pfaffenhofen
Germany
or
BERLIN-CHEMIE AG
Glienicker Weg 125,
12489 Berlin
Germany
or
Laboratorios Menarini, S.A.
Alfons XII, 587
08918 Badalona (Barcelona),
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Italy: Giant 20 mg/5 mg
Netherlands: Capenon 20 mg/5 mg
Spain: Capenon 20 mg/5 mg
Date of the last revision of this prospectus: January 2025.
Other sources of information
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of CAPENON 20 mg/5 mg FILM-COATED TABLETS in October, 2025 is around 10.72 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.